In the BioHarmony Drug Report Database
Eletriptan
Relpax (eletriptan) is a small molecule pharmaceutical. Eletriptan was first approved as Relpax on 2002-12-26. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1F, and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1E and 5-hydroxytryptamine receptor 1A.
Trade Name
|
Relpax |
|---|---|
Common Name
|
eletriptan |
ChEMBL ID
|
CHEMBL1510 |
Indication
|
migraine disorders |
Drug Class
|
Antimigraine agents (5-HT1 receptor agonists),sumatriptan derivatives |
Image (chem structure or protein)